These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34936143)

  • 21. Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.
    Vehreschild JJ; Koehler P; Lamoth F; Prattes J; Rieger C; Rijnders BJA; Teschner D
    Med Mycol; 2021 Jan; 59(1):93-101. PubMed ID: 32898264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance® registry analysis.
    Husain S; Silveira FP; Azie N; Franks B; Horn D
    Med Mycol; 2017 Apr; 55(3):269-277. PubMed ID: 27703022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens.
    Corzo-León DE; Satlin MJ; Soave R; Shore TB; Schuetz AN; Jacobs SE; Walsh TJ
    Mycoses; 2015 Jun; 58(6):325-36. PubMed ID: 25808822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Factors and Outcomes of Invasive Fungal Infections in Allogeneic Hematopoietic Cell Transplant Recipients.
    Miceli MH; Churay T; Braun T; Kauffman CA; Couriel DR
    Mycopathologia; 2017 Jun; 182(5-6):495-504. PubMed ID: 28124219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of invasive fungal infections in lung transplant recipients in Western Australia.
    Chang A; Musk M; Lavender M; Wrobel J; Yaw MC; Lawrence S; Chirayath S; Boan P
    Transpl Infect Dis; 2019 Jun; 21(3):e13085. PubMed ID: 30925010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology, risk factors, and association of antifungal prophylaxis on early invasive fungal infection in heart transplant recipients.
    Yetmar ZA; Lahr B; Brumble L; Gea Banacloche J; Steidley DE; Kushwaha S; Beam E
    Transpl Infect Dis; 2021 Oct; 23(5):e13714. PubMed ID: 34435415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis.
    Wingen-Heimann SM; Cornely OA; Vehreschild MJGT; Wisplinghoff H; Franke B; Schons M; von Bergwelt-Baildon M; Scheid C; Vehreschild JJ
    Mycoses; 2021 Apr; 64(4):437-444. PubMed ID: 33354800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients.
    Maschmeyer G; Haas A; Cornely OA
    Drugs; 2007; 67(11):1567-601. PubMed ID: 17661528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
    Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
    Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of invasive fungal disease in haematologic patients.
    Souza L; Nouér SA; Morales H; Simões B; Solza C; Queiroz-Telles F; Nucci M
    Mycoses; 2021 Mar; 64(3):252-256. PubMed ID: 33141969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
    Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
    J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center.
    Lum L; Lee A; Vu M; Strasser S; Davis R
    Transpl Infect Dis; 2020 Dec; 22(6):e13361. PubMed ID: 32510755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and Microbiological Characteristics of Proven Invasive Aspergillosis Due to Rare/Cryptic Species in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
    Yamamuro R; Kimura M; Asano-Mori Y; Abe M; Nakamura S; Umeyama T; Yamagoe S; Miyazaki Y; Ogura S; Sakoh T; Mitsuki T; Yamaguchi K; Yuasa M; Kaji D; Kageyama K; Nishida A; Taya Y; Ishiwata K; Takagi S; Yamamoto H; Yamamoto G; Uchida N; Wake A; Taniguchi S; Araoka H
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0163021. PubMed ID: 34780271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation.
    Grigg AP; Brown M; Roberts AW; Szer J; Slavin MA
    Bone Marrow Transplant; 2004 Sep; 34(5):447-53. PubMed ID: 15247932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Invasive mould disease in haematological patients].
    Ruiz-Camps I; Jarque I
    Rev Iberoam Micol; 2014; 31(4):249-54. PubMed ID: 25434346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients.
    Allinson K; Kolve H; Gumbinger HG; Vormoor HJ; Ehlert K; Groll AH
    J Antimicrob Chemother; 2008 Mar; 61(3):734-42. PubMed ID: 18238891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
    Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
    J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study.
    Kuster S; Stampf S; Gerber B; Baettig V; Weisser M; Gerull S; Medinger M; Passweg J; Schanz U; Garzoni C; Berger C; Chalandon Y; Mueller NJ; van Delden C; Neofytos D; Khanna N;
    Transpl Infect Dis; 2018 Dec; 20(6):e12981. PubMed ID: 30144374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.